1
|
Finlay MRV, Anderton M, Bailey A, Boyd S, Brookfield J, Cairnduff C, Charles M, Cheasty A, Critchlow SE, Culshaw J, Debreczeni J, Ekwuru T, Hollingsworth I, Jones N, Leroux F, Littleson M, McCarron H, McKelvie J, Mooney L, Nissink JWM, Patel J, Perkins D, Powell S, Quesada MJ, Raubo P, Sabin V, Smith J, Smith PD, Stark A, Ting A, Wang P, Wilson Z, Winter-Holt JJ, Wood JM, Wrigley GL, Yu G, Zhang P. Correction to "Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models". J Med Chem 2023. [PMID: 37341555 DOI: 10.1021/acs.jmedchem.3c00198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/22/2023]
|
2
|
Stockley ML, Benedetti G, Blencowe P, Boulton SJ, Boyd SM, Calder M, Charles MD, Edwardes LV, Ekwuru T, Ferdinand A, Finch H, Galbiati A, Geo L, Grande D, Grinkevich V, Higgins GS, Holliday ND, Krajewski WW, MacDonald E, Majithiya JB, McCarron H, McWhirter CL, Patel V, Pedder C, Rajendra E, Ranzani M, Rigoreau LJM, Robinson HMR, Schaedler T, Sirina J, Smith GCM, Swarbrick ME, Turnbull AP, Willis S, Zemla A, Heald RA. Correction to "Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta". J Med Chem 2023; 66:3649-3649. [PMID: 36815444 DOI: 10.1021/acs.jmedchem.3c00204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
|
3
|
Stockley ML, Ferdinand A, Benedetti G, Blencowe P, Boyd SM, Calder M, Charles MD, Edwardes LV, Ekwuru T, Finch H, Galbiati A, Geo L, Grande D, Grinkevich V, Holliday ND, Krajewski WW, MacDonald E, Majithiya JB, McCarron H, McWhirter CL, Patel V, Pedder C, Rajendra E, Ranzani M, Rigoreau LJM, Robinson HMR, Schaedler T, Sirina J, Smith GCM, Swarbrick ME, Turnbull AP, Willis S, Heald RA. Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta. J Med Chem 2022; 65:13879-13891. [PMID: 36200480 DOI: 10.1021/acs.jmedchem.2c01142] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Human DNA polymerase theta (Polθ), which is essential for microhomology-mediated DNA double strand break repair, has been proposed as an attractive target for the treatment of BRCA deficient and other DNA repair pathway defective cancers. As previously reported, we recently identified the first selective small molecule Polθ in vitro probe, 22 (ART558), which recapitulates the phenotype of Polθ loss, and in vivo probe, 43 (ART812), which is efficacious in a model of PARP inhibitor resistant TNBC in vivo. Here we describe the discovery, biochemical and biophysical characterization of these probes including small molecule ligand co-crystal structures with Polθ. The crystallographic data provides a basis for understanding the unique mechanism of inhibition of these compounds which is dependent on stabilization of a "closed" enzyme conformation. Additionally, the structural biology platform provided a basis for rational optimization based primarily on reduced ligand conformational flexibility.
Collapse
Affiliation(s)
- Martin L Stockley
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Amanda Ferdinand
- Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K
| | - Giovanni Benedetti
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Peter Blencowe
- Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K
| | - Susan M Boyd
- CompChem Solutions Ltd, St John's Innovation Centre, Cowley Rd, CambridgeCB4 0WS, U. K
| | - Mat Calder
- Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K
| | - Mark D Charles
- Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K
| | - Lucy V Edwardes
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Tennyson Ekwuru
- Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K
| | - Harry Finch
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | | | - Lerin Geo
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Diego Grande
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Vera Grinkevich
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Nicholas D Holliday
- Excellerate Bioscience Ltd., BioCity, Pennyfoot Street, NottinghamNG1 1GF, U. K
| | - Wojciech W Krajewski
- Cancer Research Horizons Therapeutic Innovation, The Francis Crick Institute, 1 Midland Road, LondonNW1 1AT, U. K
| | - Ellen MacDonald
- Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K
| | - Jayesh B Majithiya
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Hollie McCarron
- Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K
| | - Claire L McWhirter
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Viral Patel
- Excellerate Bioscience Ltd., BioCity, Pennyfoot Street, NottinghamNG1 1GF, U. K
| | - Chris Pedder
- Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K
| | - Eeson Rajendra
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Marco Ranzani
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Laurent J M Rigoreau
- Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K
| | - Helen M R Robinson
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Theresia Schaedler
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Julija Sirina
- Excellerate Bioscience Ltd., BioCity, Pennyfoot Street, NottinghamNG1 1GF, U. K
| | - Graeme C M Smith
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| | - Martin E Swarbrick
- Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K
| | - Andrew P Turnbull
- Cancer Research Horizons Therapeutic Innovation, The Francis Crick Institute, 1 Midland Road, LondonNW1 1AT, U. K
| | - Simon Willis
- Cancer Research Horizons Therapeutic Innovation, The Francis Crick Institute, 1 Midland Road, LondonNW1 1AT, U. K
| | - Robert A Heald
- Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K
| |
Collapse
|
4
|
Zatreanu D, Robinson HMR, Alkhatib O, Boursier M, Finch H, Geo L, Grande D, Grinkevich V, Heald RA, Langdon S, Majithiya J, McWhirter C, Martin NMB, Moore S, Neves J, Rajendra E, Ranzani M, Schaedler T, Stockley M, Wiggins K, Brough R, Sridhar S, Gulati A, Shao N, Badder LM, Novo D, Knight EG, Marlow R, Haider S, Callen E, Hewitt G, Schimmel J, Prevo R, Alli C, Ferdinand A, Bell C, Blencowe P, Bot C, Calder M, Charles M, Curry J, Ekwuru T, Ewings K, Krajewski W, MacDonald E, McCarron H, Pang L, Pedder C, Rigoreau L, Swarbrick M, Wheatley E, Willis S, Wong AC, Nussenzweig A, Tijsterman M, Tutt A, Boulton SJ, Higgins GS, Pettitt SJ, Smith GCM, Lord CJ. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat Commun 2021; 12:3636. [PMID: 34140467 PMCID: PMC8211653 DOI: 10.1038/s41467-021-23463-8] [Citation(s) in RCA: 144] [Impact Index Per Article: 48.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Accepted: 04/30/2021] [Indexed: 02/05/2023] Open
Abstract
To identify approaches to target DNA repair vulnerabilities in cancer, we discovered nanomolar potent, selective, low molecular weight (MW), allosteric inhibitors of the polymerase function of DNA polymerase Polθ, including ART558. ART558 inhibits the major Polθ-mediated DNA repair process, Theta-Mediated End Joining, without targeting Non-Homologous End Joining. In addition, ART558 elicits DNA damage and synthetic lethality in BRCA1- or BRCA2-mutant tumour cells and enhances the effects of a PARP inhibitor. Genetic perturbation screening revealed that defects in the 53BP1/Shieldin complex, which cause PARP inhibitor resistance, result in in vitro and in vivo sensitivity to small molecule Polθ polymerase inhibitors. Mechanistically, ART558 increases biomarkers of single-stranded DNA and synthetic lethality in 53BP1-defective cells whilst the inhibition of DNA nucleases that promote end-resection reversed these effects, implicating these in the synthetic lethal mechanism-of-action. Taken together, these observations describe a drug class that elicits BRCA-gene synthetic lethality and PARP inhibitor synergy, as well as targeting a biomarker-defined mechanism of PARPi-resistance.
Collapse
Affiliation(s)
- Diana Zatreanu
- CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - Helen M R Robinson
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Omar Alkhatib
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Marie Boursier
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Harry Finch
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Lerin Geo
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Diego Grande
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Vera Grinkevich
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Robert A Heald
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Sophie Langdon
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Jayesh Majithiya
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Claire McWhirter
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Niall M B Martin
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Shaun Moore
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Joana Neves
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Eeson Rajendra
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Marco Ranzani
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Theresia Schaedler
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Martin Stockley
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Kimberley Wiggins
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
| | - Rachel Brough
- CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - Sandhya Sridhar
- CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - Aditi Gulati
- CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - Nan Shao
- CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - Luned M Badder
- The Breast Cancer Now Research Unit, King's College London, London, UK
| | - Daniela Novo
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - Eleanor G Knight
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - Rebecca Marlow
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
- The Breast Cancer Now Research Unit, King's College London, London, UK
| | - Syed Haider
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - Elsa Callen
- Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA
| | | | - Joost Schimmel
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Remko Prevo
- Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, UK
| | - Christina Alli
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Amanda Ferdinand
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Cameron Bell
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Peter Blencowe
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Chris Bot
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Mathew Calder
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Mark Charles
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Jayne Curry
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Tennyson Ekwuru
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Katherine Ewings
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Wojciech Krajewski
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Ellen MacDonald
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Hollie McCarron
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Leon Pang
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Chris Pedder
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Laurent Rigoreau
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Martin Swarbrick
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Ed Wheatley
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Simon Willis
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Ai Ching Wong
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
| | - Andre Nussenzweig
- Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Marcel Tijsterman
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Andrew Tutt
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
- The Breast Cancer Now Research Unit, King's College London, London, UK
| | - Simon J Boulton
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
- The Francis Crick Institute, London, UK
| | - Geoff S Higgins
- Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, UK
| | - Stephen J Pettitt
- CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
| | - Graeme C M Smith
- Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
| | - Christopher J Lord
- CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
| |
Collapse
|
5
|
Finlay MRV, Anderton M, Bailey A, Boyd S, Brookfield J, Cairnduff C, Charles M, Cheasty A, Critchlow SE, Culshaw J, Ekwuru T, Hollingsworth I, Jones N, Leroux F, Littleson M, McCarron H, McKelvie J, Mooney L, Nissink JWM, Perkins D, Powell S, Quesada MJ, Raubo P, Sabin V, Smith J, Smith PD, Stark A, Ting A, Wang P, Wilson Z, Winter-Holt JJ, Wood JM, Wrigley GL, Yu G, Zhang P. Discovery of a Thiadiazole–Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models. J Med Chem 2019; 62:6540-6560. [DOI: 10.1021/acs.jmedchem.9b00260] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- M. Raymond V. Finlay
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Mark Anderton
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Andrew Bailey
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Scott Boyd
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Joanna Brookfield
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - Ceri Cairnduff
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - Mark Charles
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - Anne Cheasty
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - Susan E. Critchlow
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Janet Culshaw
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Tennyson Ekwuru
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - Ian Hollingsworth
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Neil Jones
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - Fred Leroux
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - Mairi Littleson
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Hollie McCarron
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - Jennifer McKelvie
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - Lorraine Mooney
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - J. Willem M. Nissink
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - David Perkins
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Steve Powell
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Mar Jimenez Quesada
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - Piotr Raubo
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Verity Sabin
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - James Smith
- Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
| | - Peter D. Smith
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Andrew Stark
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Attilla Ting
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Peng Wang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Zena Wilson
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Jon J. Winter-Holt
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - J. Matthew Wood
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Gail L. Wrigley
- Oncology, IMED Biotech Unit, AstraZeneca, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0FZ, United Kingdom
| | - Guoqing Yu
- Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Peng Zhang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| |
Collapse
|
6
|
Mitchell L, McCarron H, Weinstein A, Gaugler JE. ENGAGING ADULT DAY SERVICE SITES IN THE ADS PLUS PRAGMATIC TRIAL. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- L Mitchell
- Minneapolis Veterans Administration Medical Center, Minnneapolis, Minnesota, United States
| | - H McCarron
- Families and LTC Projects, University of Minnesota, Minneapolis, MN, USA
| | - A Weinstein
- Families and LTC Projects, University of Minnesota, Minneapolis, MN, USA
| | - J E Gaugler
- Center on Aging, School of Nursing, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
7
|
McCarron H, Finlay J, Sims T, Nikzad-Terhune K, Gaugler J. STAKEHOLDER ENGAGEMENT TO ENHANCE INTERVENTIONS FOR FAMILY CAREGIVERS OF PEOPLE WITH DEMENTIA. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | | | - T Sims
- Minnesota State University, Mankato
| | | | | |
Collapse
|
8
|
Zmora R, Mitchell L, Finlay J, Peterson C, McCarron H, Jutkowitz E, Gaugler J. SIX-MONTH EFFICACY OF REMOTE ACTIVITY MONITORING FOR PERSONS WITH DEMENTIA AND THEIR FAMILY CAREGIVERS. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - L Mitchell
- Minneapolis Veterans Administration Medical Center
| | | | | | | | - E Jutkowitz
- Center for Gerontology and Healthcare Research, School of Public Health, Brown University, Providence, RI, USA
| | | |
Collapse
|
9
|
Abstract
Nitric oxide (NO)-mediated and NO-independent mechanisms of endothelium-dependent vasodilatation involve Ca(2+)-dependent K(+) (K(Ca)) channels. We examined the role in vivo of K(Ca) channels in NO-independent vasodilatation in hypercholesterolemia. Hindlimb vascular conductance was measured at rest and after aortic injection of ACh, bradykinin (BK), and sodium nitroprusside in anesthetized control and cholesterol-fed rabbits. Conductances were measured before and after treatment with the NO synthase antagonist N(omega)-nitro-L-arginine methyl ester (L-NAME, 10 mg/kg) or K(Ca) blockers tetraethylammonium (30 mg/kg), charybdotoxin (10 microgram/kg), and apamin (50 microgram/kg). The contribution of NO to basal conductance was greater in control than in cholesterol-fed rabbits [2.2 +/- 0.4 vs. 1.1 +/- 0.3 (SE) ml. min(-1). kg(-1). 100 mmHg(-1), P < 0.05], but the NO-independent K(Ca) channel-mediated component was greater in the cholesterol-fed than in the control group (1.1 + 0.4 vs. 0.3 +/- 0.1 ml. min(-1). kg(-1). 100 mmHg(-1), P < 0.05). Maximum conductance response to ACh and BK was less in cholesterol-fed than in control rabbits, and the difference persisted after L-NAME (ACh: 7.7 +/- 0.7 vs. 10.1 +/- 0.5 ml. min(-1). kg(-1). 100 mmHg(-1), P < 0.005). Blockade of K(Ca) channels with tetraethylammonium or charybdotoxin + apamin almost completely abolished L-NAME-resistant vasodilatation after ACh or BK. The magnitude of K(Ca)-mediated vasodilatation after ACh or BK was impaired in hypercholesterolemic rabbits. Vasodilator responses to nitroprusside did not differ between groups. In vivo, hypercholesterolemia is associated with an altered balance between NO-mediated and NO-independent K(Ca) channel contributions to resting vasomotor tone and impairment of both mechanisms of endothelium-dependent vasodilatation.
Collapse
Affiliation(s)
- R W Jeremy
- Department of Medicine, University of Sydney, Sydney, New South Wales 2006, Australia.
| | | |
Collapse
|
10
|
Jeremy RW, McCarron H, Sullivan D. Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilatation in the hypercholesterolemic rabbit. Response according to treatment duration, anatomic site, and sex. Circulation 1996; 94:498-506. [PMID: 8759095 DOI: 10.1161/01.cir.94.3.498] [Citation(s) in RCA: 71] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Nitric oxide (NO) may protect arteries against atherosclerosis. In the present study, we examined whether dietary L-arginine, the precursor of NO, could chronically preserve endothelium-dependent vasodilatation in vivo and/or limit atherogenesis. METHODS AND RESULTS Rabbits were randomized according to sex to receive 2% dietary cholesterol, with or without L-arginine (2.25% solution), for 7 or 14 weeks. Hindlimb vasodilator responses to acetylcholine and nitroprusside were measured with an electromagnetic flow probe. Atherosclerosis was measured with planimetry of aortic lesions stained with Oil-Red-O. In rabbits administered L-arginine, plasma arginine levels increased to 483 +/- 30 mumol/L at 3 weeks (mean +/- SEM, P < .0001 versus control animals) but declined to 224 +/- 25 mumol/L at 7 weeks (P = .02) and to 100 +/- 23 mumol/L at 14 weeks (NS versus control animals). At 7 weeks, peak hindlimb conductance in response to acetylcholine in cholesterol-fed males was 249 +/- 49% of baseline compared with 332 +/- 9% in control animals (P = .04), but peak response in arginine-fed rabbits (314 +/- 24%) did not differ from that of control animals. At 14 weeks, peak responses to acetylcholine were equally reduced in males fed cholesterol with (266 +/- 21%, P = .02 versus control) or without (263 +/- 13%, P = .01 versus control) L-arginine. Similar impairment of endothelium-dependent vasodilatation was seen in females at 14 weeks. Vasodilator responses to nitroprusside did not differ from those of control animals in any treatment group. After 14 weeks, atherosclerosis was less in the descending aorta of arginine-fed males (16 +/- 4% surface area) than that of males fed cholesterol only (42 +/- 8%, P = .04), but no treatment benefit was seen in the ascending aorta or in females. CONCLUSIONS Dietary L-arginine supplementation causes an early rise in plasma arginine levels, with limitation of atherosclerosis in the descending aorta and preservation of endothelium-dependent vasodilatation in resistance arteries, but this treatment effect is not sustained. Dietary L-arginine may not be of long-term benefit in the prevention of atherosclerosis in humans.
Collapse
Affiliation(s)
- R W Jeremy
- Department of Medicine, University of Sydney, Australia
| | | | | |
Collapse
|
11
|
Abstract
This study examined the relations between age, arterial distensibility, and systemic hemodynamics in patients with the Marfan syndrome. The study group included 170 patients referred to a specialist clinic, of whom 55 (age 26 +/- 12 years) were diagnosed as having Marfan syndrome. The remaining 115 patients (age 25 +/- 14 years) formed a control group. Each patient underwent echocardiographic examination, with measurement of ascending aorta diameter at end-diastole and end-systole, and aortic flow velocities. The elastic properties of the aorta were indexed by calculation of aortic distensibility, wall stiffness, and systemic pulse wave velocity. Mean end-diastolic aortic diameter in the Marfan group (38 +/- 9 mm) was greater than that in the controls (26 +/- 4 mm, p < 0.01). Resting heart rate and aortic flow velocities were similar in the 2 groups, but systemic arterial pulse pressure was greater in the Marfan group (50 +/- 12 mm Hg) than in the controls (41 +/- 8 mm Hg, p < 0.01). Aortic diameter increased with age in both groups, but at all ages the Marfan group exhibited greater aortic diameters (p < 0.05). Aortic distensibility was less in the Marfan group (2.6 +/- 1.3 cm2.dynes-1 x10(-6)) than in the controls (6.2 +/- 2.1 cm2.dynes-1 x 10(-6), p < 0.01), and the aortic wall stiffness index was greater in the Marfan group (7.9 +/- 3.4) than in the controls (2.8 +/- 0.6, p < 0.01). Aortic wall stiffness increased with age and aortic diameter, but at all ages the Marfan group exhibited a stiffer aorta for a given diameter than did the controls.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- R W Jeremy
- Department of Cardiology, Royal Prince Alfred Hospital, New South Wales, Australia
| | | | | | | | | | | |
Collapse
|
12
|
Geiser F, Augee ML, McCarron H, Raison JK. Correlates of torpor in the insectivorous dasyurid marsupial Sminthopsis murina. Aust Mammalogy 1984. [DOI: 10.1071/am84020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Body temperatures, oxygen consumption and the thermal response of liver mitochondrial membranes of the Common Dunnart, Sminthopsis murina, were measured during winter and the summer mating season. In winter body temperatures for S. murina during spontaneous torpor were as low as 15oC and oxygen consumption was reduced to 6% of normothermic resting animals. In summer animals remained normothermic. For the winter animals liver mitochondrial succinate oxidase and succinate: cytochrome c reductase showed a constant apparent Arrhenius activation energy (Ea) over the temperature range 6 to 40oC. For summer animals Ea increased below about 20oC. The temperature coefficient for the motion of spin labels intercalated with membrane lipids increased below about 8oC for membranes from winter animals and below 20oC for summer animals.
Collapse
|